Download PDF
Horm Metab Res 2016; 48(06): 399-403
DOI: 10.1055/s-0042-101028
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

A Study of Serum Soluble CD 163 Levels in Women with Polycystic Ovary Syndrome

A. S. Oruç
1   Zekai Tahir Burak Women’s Health Education and Research Hospital, Department of Reproductive Endocrinology, Ankara, Turkey
2   Present address: Obstetrics and Gynecology Department, Güven Hospital, Ankara, Turkey
,
N. Yilmaz
1   Zekai Tahir Burak Women’s Health Education and Research Hospital, Department of Reproductive Endocrinology, Ankara, Turkey
,
H. A. İnal
1   Zekai Tahir Burak Women’s Health Education and Research Hospital, Department of Reproductive Endocrinology, Ankara, Turkey
,
Ü. Görkem
3   Department of Obstetrics and Gynecology, Hitit University, Çorum, Turkey
,
P. Gulsen
1   Zekai Tahir Burak Women’s Health Education and Research Hospital, Department of Reproductive Endocrinology, Ankara, Turkey
,
M. Uğur
1   Zekai Tahir Burak Women’s Health Education and Research Hospital, Department of Reproductive Endocrinology, Ankara, Turkey
,
U. Buyukkagnici
4   Zekai Tahir Burak Women’s Health Education and Research Hospital, Department of Biochemistry, Ankara, Turkey
› Author Affiliations
Further Information

Publication History

received 04 November 2015

accepted 07 January 2016

Publication Date:
17 March 2016 (online)

Also available at
    Permissions and Reprints

Abstract

The aim of this study was to determine serum soluble CD163 levels in patients with polycystic ovary syndrome and its relation to clinical and metabolic parameters. Eighty-four women aged 18–45 years, 43 with polycystic ovary syndrome and 41 controls were recruited in this case-control study. Serum sCD163 levels of the groups were compared. Other metabolic, hormonal, and clinical parameters including, body mass index, HOMA-IR, highly sensitive C- reactive protein, glucose, glycated hemoglobin, lipids, luteinizing hormone, and total testosterone and waist/hip circumference were also investigated. Patients were further subgrouped according to body mass index and sCD163 levels were investigated in obese and normal weight subjects. We performed a multiple regression analysis to investigate the independent predictors affecting soluble CD163 levels. Significantly higher soluble CD163 levels were found in patients with polycystic ovary syndrome (2.11±0.65 ng/ml vs. 1.69±0.85 ng/ml, p=0.012). We detected positive correlations of sCD163 with total testosterone, total cholesterol, and luteinizing hormone (r=0.330, p=0.002, r=0.356, p<0.001 and r=0.239, p=0.030, respectively). In the multiple linear regression analysis, total testosterone was the variable associated with the elevation of serum soluble CD163 levels. Soluble CD163, which is identified as a marker of inflammation and type II diabetes, is elevated in polycystic ovary syndrome. Elevated sCD163 levels were found to be associated with total testosterone. Further studies to elucidate the exact mechanism underlying the elevation of serum soluble CD163 in polycystic ovary syndrome are needed.

Key words

soluble CD163 - polycystic ovary syndrome - inflammation - obesity
 

  • References

  • 1 The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
    Google Scholar
  • 2 Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008; 23: 462-477
    CrossrefPubMedGoogle Scholar
  • 3 Shakeri-Manesch S, Zeyda M, Huber J, Ludvik B, Prager G, Stulnig TM. Diminished up regulation of visceral adipose heme oxygenase-1 correlates with waist-to-hip ratio and insulin resistance. Int J Obes (Lond) 2009; 33: 1257-1264
    CrossrefPubMedGoogle Scholar
  • 4 Thomsen HH, Møller HJ, Trolle C, Groth KA, Skakkebæk A, Bojesen A, Høst C, Gravholt CH. The macrophage low-grade inflammation marker sCD163 is modulated by exogenous sex steroids. Endocr Connect 2013; 8: 216-224
    PubMedGoogle Scholar
  • 5 González F. Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012; 77: 300-305
    CrossrefPubMedGoogle Scholar
  • 6 Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. Themolecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005; 26: 251-282
    CrossrefPubMedGoogle Scholar
  • 7 Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 2010; 47: 1650-1660
    CrossrefPubMedGoogle Scholar
  • 8 Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metallo proteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733
    CrossrefPubMedGoogle Scholar
  • 9 Etzerodt A, Maniecki MB, Møller K, Møller HJ, Moestrup SK. Tumor necrosis factor α-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol 2010; 88: 1201-1205
    CrossrefPubMedGoogle Scholar
  • 10 Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf) 2012; 77: 385-390
    CrossrefPubMedGoogle Scholar
  • 11 Parkner T, Sørensen LP, Nielsen AR, Fischer CP, Bibby BM, Nielsen S, Pedersen BK, Møller HJ. Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia 2012; 55: 1856-1862
    CrossrefPubMedGoogle Scholar
  • 12 Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999; 48: 437-441
    CrossrefPubMedGoogle Scholar
  • 13 Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95: 2038-2049
    CrossrefPubMedGoogle Scholar
  • 14 Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Györi G, Zlabinger GJ, Stulnig TM. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 2007; 31: 1420-1428
    CrossrefPubMedGoogle Scholar
  • 15 Sporrer D, Weber M, Wanninger J, Weigert J, Neumeier M, Stögbauer F, Lieberer E, Bala M, Kopp A, Schäffler A, Buechler C. Adiponectin down regulates CD163 whose cellular and soluble forms are elevated in obesity. Eur J ClinInvest 2009; 39: 671-679
    PubMedGoogle Scholar
  • 16 Møller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjærg-Hansen A. Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 2011; 57: 291-297
    CrossrefPubMedGoogle Scholar
  • 17 Huang G, Coviello A. Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2012; 19: 512-519
    CrossrefPubMedGoogle Scholar
  • 18 Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, Hall JE. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997; 82: 2248-2256
    CrossrefPubMedGoogle Scholar
  • 19 Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley Jr WF. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988; 66: 165-172
    CrossrefPubMedGoogle Scholar
  • 20 Asemi Z, Esmaillzadeh A. DASH diet, insulin resistance, and serum hs-CRP in polycystic ovary syndrome: a randomized controlled trial. Horm Metab Res 2015; 47: 232-238
    Google Scholar
  • 21 Lindholm A, Blomquist C, Bixo M, Dahlbom I, Hansson T, SundströmPoromaa I, Burén J. No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls. Hum Reprod 2011; 26: 1478-1485
    CrossrefPubMedGoogle Scholar
  • 22 Sumithra NU, Lakshmi RL, Leela Menon N, Subhakumari KN, Sheejamol VS. Evaluation of Oxidative Stress and hsCRP in Polycystic Ovarian Syndrome in a Tertiary Care Hospital. Indian J. Clin Biochem 2015; 30: 161-166
    CrossrefPubMedGoogle Scholar
  • 23 Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160-2165
    CrossrefPubMedGoogle Scholar
  • 24 Tarkun I, Arsan Z, Turemen E, Sahin T, Duman C. Enthothelial dysfuction in young women with polycystic ovary syndrome: Relationship with insulin resistance and low grade inflammation. J Clin Endocrinol Metab 2004; 89: 5592-5596
    CrossrefPubMedGoogle Scholar
  • 25 Arikan S, Bahceci M, Tuzcu A, Kale E, Gökalp D. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. Gynecol Endocrinol 2010; 26: 161-166
    CrossrefPubMedGoogle Scholar
  • 26 Karoli R, Fatima J, Siddiqi Z, Vatsal P, Sultania AR, Maini S. Study of early atherosclerotic markers in women with polycystic ovary syndrome. Indian J Endocrinol Metab 2012; 16: 1004-1008
    CrossrefPubMedGoogle Scholar
  • 27 Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113-116
    CrossrefPubMedGoogle Scholar
  • 28 Polotsky AJ, Allshouse A, Crawford SL, Harlow SD, Khalil N, Santoro N, Legro RS. Relative contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women. J Clin Endocrinol Metab 2012; 97: E868-E877
    CrossrefPubMedGoogle Scholar
  • 29 Garcia V, Orostica L, Poblete C, Rosas C, Astorga I, Romero C, Vega M. Endometria from Obese PCOS Women with Htperinsulinemia Exhibit altered Adiponectin Signaling. Horm Metab Res 2015; 47: 901-909
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 González F, Nair KS, Daniels JK, Basal E, Schimke JM, Blair HE. Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J Clin Endocrinol Metab 2012; 97: 2836-2843
    CrossrefPubMedGoogle Scholar